SCHEMBL3133690

SCHEMBL3133690

N#Cc1coc(-c2ccccc2N)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
HSD17B10 Q99714 3/20 0.35
KDM4E B2RXH2 4/20 0.35
GAA P10253 4/20 0.35
TSHR P16473 1/20 0.34
HPGD P15428 2/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
ESR1 P03372 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901045 0.74 TSHR (0.44) ALDH1A1CHRM2CHRM4CHRM5CHRM1
SCHEMBL18940861 0.71 ALDH1A1 (0.52) ALDH1A1L3MBTL1HSD17B10KDM4EGAA
SCHEMBL1705257 0.68 ALDH1A1 (0.58) ALDH1A1L3MBTL1HSD17B10KDM4EGAA
SCHEMBL396202 0.68 ADRA2C (0.59) ALDH1A1L3MBTL1HSD17B10PDK2ADRA2C
SCHEMBL5154599 0.66
SCHEMBL20116875 0.66 ALDH1A1 (0.45) ALDH1A1L3MBTL1KDM4EGAAPDK2
SCHEMBL20040430 0.66 ALDH1A1 (0.45) ALDH1A1L3MBTL1HSD17B10KDM4EGAA
Water SCHEMBL2442515 0.65 ALDH1A1 (0.93) ALDH1A1L3MBTL1HSD17B10KDM4EGAA
SCHEMBL24768621 0.64 ADORA2A (0.50) ALDH1A1L3MBTL1HSD17B10KDM4EGAA
SCHEMBL30072279 0.64 ADORA2A (0.50) ALDH1A1L3MBTL1HSD17B10KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966218-B1 NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES BAYER SCHERING PHARMA AG (DE) 2010-07-14 EP disclosed